Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Breast Cancer. 2014 Jun;14(3):205-11. doi: 10.1016/j.clbc.2013.10.018. Epub 2013 Oct 26.

Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study.

Author information

  • 1University of Wisconsin Carbone Cancer Center, Madison, WI; Hematology/Oncology Division, Department of Medicine, University of Wisconsin, Madison, WI. Electronic address: mburkard@wisc.edu.
  • 2University of Wisconsin Carbone Cancer Center, Madison, WI; Hematology/Oncology Division, Department of Medicine, University of Wisconsin, Madison, WI.
  • 3University of Wisconsin Carbone Cancer Center, Madison, WI.
  • 4Bellin Memorial Hospital, Green Bay, WI.
  • 5Columbia St Mary's, Milwaukee, WI.
  • 6Fox Valley Hematology and Oncology, Appleton, WI.
  • 7Aurora Cancer Care, Wauwatosa, WI.
  • 8Gundersen Lutheran Health System, Lacrosse, WI.
  • 9University of Wisconsin Carbone Cancer Center, Madison, WI; Departments of Biostatistics and Medical Informatics and Statistics, University of Wisconsin, Madison, WI.

Abstract

INTRODUCTION:

Dose-dense therapies have had a major effect on reducing toxicity and improving outcomes in breast cancer. A combination of TC every 3 weeks has emerged as a common chemotherapy regimen used for treatment of node-negative or lower-risk node-positive breast cancer. We tested whether it is feasible to deliver TC on a dose-dense schedule, with therapy completed within 10 weeks.

PATIENTS AND METHODS:

We enrolled women with early stage breast cancer on a single-arm phase II study of adjuvant dose-dense TC through a regional oncology network. All women completed primary surgery before accrual, and subsequent therapy with TC was deemed appropriate by the treating physician. Planned treatment was docetaxel 75 mg/m(2) plus cyclophosphamide 600 mg/m(2) every 2 weeks for 4 cycles with subcutaneous pegfilgrastim 6 mg administered 24 to 48 hours after the administration of each chemotherapy cycle.

RESULTS:

Of 42 women enrolled, 41 were evaluable using prespecified criteria. Of these, 37 (90.2%) completed therapy within 10 weeks and 34 (83%) completed therapy at 8 weeks without dose modification. Rates of neuropathy were similar to that reported previously. The rate of neutropenic fever was low (2.5%). Rash and plantar-palmar erythrodythesia were common and reached grade 3 in 4 subjects (9.8%).

CONCLUSION:

Dose-dense TC is feasible with tolerability profiles similar to standard TC and a low likelihood of neutropenic fever. This study supports further clinical development of this 8-week adjuvant chemotherapy regimen.

Copyright © 2014 Elsevier Inc. All rights reserved.

KEYWORDS:

Chemotherapy; Febrile neutropenia; Granulocyte-colony stimulating factor; Palmar-plantar erythrodysthesia; Pegfilgrastim

PMID:
24342730
[PubMed - indexed for MEDLINE]
PMCID:
PMC4000576
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk